Beijing Do-Health Biotechnology

Do-Health is a clinical-stage biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. The company has developed a proprietary ADC platform featuring novel linkers and payloads designed to improve stability and therapeutic index. Its pipeline includes several candidates targeting HER2, Trop2, and other validated tumor antigens, with multiple programs in clinical trials. Do-Health has established significant partnerships, including a major licensing agreement with Janssen (Johnson & Johnson) for its ADC technology. The company is supported by prominent investors such as Hillhouse Capital and Matrix Partners China.